Organon & Co. OGN revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Organon & Co. reported revenue across 33 products and services; the largest, Nexplanon Implanon NXT, was $921M, 14.8% of the filed sum (-4.4% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Nexplanon Implanon NXT$921M14.8%-4.4% yoy
- Zetia$342M5.5%+7.9% yoy
- Other Sundry Established Brands$338M5.4%+3.0% yoy
- Atozet$324M5.2%-31.5% yoy
- Other Non Opiod Pain Bone And Dermatology$301M4.8%+2.0% yoy
- Arcoxia$265M4.3%-1.9% yoy
- Follistim AQ$264M4.2%+11.4% yoy
- Nasonex$262M4.2%-5.1% yoy
- +25 more members in the filing
Members sum to the consolidated $6.22B for this period.
- Outside the United States$4.61Bshare n/a-4.5% yoy
- Europe And Canada$1.62Bshare n/a-8.2% yoy
- United States$1.6Bshare n/a+2.0% yoy
- Latin America Middle East Russia And Africa$1.07Bshare n/a+3.7% yoy
- Asia Pacific And Japan$1Bshare n/a-4.8% yoy
- China$829Mshare n/a-2.1% yoy
- Other countries$93Mshare n/a-32.1% yoy
member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.
- Nexplanon Implanon NXT$230M14.8%-4.2% yoy
- Zetia$96M6.2%+29.7% yoy
- Other Sundry Established Brands$96M6.2%+10.3% yoy
- Atozet$80M5.1%-7.0% yoy
- Other Non Opiod Pain Bone And Dermatology$79M5.1%-1.2% yoy
- Hadlima$79M5.1%+58.0% yoy
- +28 more members in the filing
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.